Eli Lilly Latest US Company to Commit to Domestic Investments

Eli Lilly (LLY) plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S., as the company looks to ramp up its domestic drug productions amid the threat of possible tariffs.

Eli Lilly, which had committed to $23 billion in domestic investments from 2020-2024, expects the facilities will “create more than 3,000 jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians,” along with nearly 10,000 construction jobs. Site locations are expected to be announced late this year with the plants coming online within five years. 

The announcement after President Trump reportedly said last week that he planned to impose tariffs of at least 25% on pharmaceutical imports. A few days later, Trump met privately with pharmaceutical CEOs, including Eli Lilly’s David Ricks, and urged them to shift manufacturing to the U.S., according to a report from Bloomberg.

Shares of Eli Lilly rose 1% Wednesday afternoon and are up about 18% since the start of the year.

Apple Announced Massive Domestic Investment Earlier This Week

Apple (AAPL) said on Monday it plans to spend more than $500 billion in the U.S. over the next four years, including on the production of artificial intelligence servers previously made abroad at a new Texas-based factory. Apple said it plans to hire around 20,000 people for the Houston facility, which it expects will open in 2026. 

Meanwhile, Intel (INTC) has been at the subject of speculation that Taiwan Semiconductor Manufacturing Co. (TSM) could buy its struggling foundry business, creating a new U.S.-based chipmaking entity with support from the world’s largest semiconductor manufacturer. Those discussions come as Vice President JD Vance said the Trump administration wants AI chips to be designed and manufactured domestically.